Fengying Wu - Concepedia

Author

Fengying Wu

Tongji University ORCID

Also Known As

F Wu, F. Wu, F.T.H. Wu, FENG-YING WU, Fang-Ting Wu, Fangbin Wu, Feng-Ying Wu, Feng-ying Wu, Fenghua Wu, Fengying Wu

170

Publications

4.1K

Citations

H-Index

Concepts

All Affiliations

Tongji University Shanghai Pulmonary Hospital Zhejiang Cancer Hospital Henan Cancer Hospital Jiangsu Hengrui Medicine (China)

About

Fengying Wu is an author at Tongji University specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	1.3K
2	Health Sciences	5	5	614
3	Engineering	3	3	64
4	Public Health	1	1	41
5	Allergy	1	1	134

Fengying Wu

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer Fengying Wu, Jue Fan, Yayi He, Nature Communications	2021	759
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial Caicun Zhou, Gongyan Chen, Yunchao Huang, The Lancet Respiratory Medicine OncologyClinical TrialsChemotherapy-naive PatientsImmune Checkpoint InhibitorPharmacotherapy	2020	488
Lung cancer in China: current and prospect Fengying Wu, Lei Wang, Caicun Zhou Current Opinion in Oncology	2020	308
Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study Caicun Zhou, Xingya Li, Qiming Wang, Journal of Clinical Oncology	2020	197
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers Tao Jiang, Xiaofeng Xu, Meng Qiao, BMC Cancer	2018	136
Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors Xiangling Chu, Jing Zhao, Juan Zhou, Lung Cancer AllergyMedicineImmune Checkpoint InhibitorsImmunologyImmune Checkpoint Inhibitor	2020	134
Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7 Jia Yu, Bo Qin, Fengying Wu, Cell Reports	2017	99
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients Kunlatida Maneenil, Zhiqiang Xue, Ming Liu, Clinical Lung Cancer Mayo Clinic ExperienceMedicineSurgical PathologyPathologyBronchial Neoplasm	2017	97
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway Fei Zhou, Jianguo Sun, Lingyun Ye, Experimental Hematology and Oncology	2023	81
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial Caicun Zhou, Gongyan Chen, Yunchao Huang, Journal of Thoracic Oncology Advanced Nonsquamous NsclcOncologyCamrelizumab Plus CarboplatinMedicineClinical Trials	2023	65

Page 1